GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » 5-Year Yield-on-Cost %

MedMira (MedMira) 5-Year Yield-on-Cost % : 0.00 (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is MedMira 5-Year Yield-on-Cost %?

MedMira's yield on cost for the quarter that ended in Jan. 2024 was 0.00.


The historical rank and industry rank for MedMira's 5-Year Yield-on-Cost % or its related term are showing as below:



MMIRF's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.615
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of MedMira's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, MedMira's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where MedMira's 5-Year Yield-on-Cost % falls into.



MedMira 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of MedMira is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

MedMira  (OTCPK:MMIRF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


MedMira 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of MedMira's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

MedMira Reports Third Quarter Results FY2021

By GlobeNewswire GlobeNewswire 06-30-2021

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018